<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An inherent defect of erythroid differentiation at the colony-forming unit blast (CFU-blast) compartment and (or) an impaired response of early erythroid progenitors (BFU-E) to growth stimulation are both considered to contribute to <z:hpo ids='HP_0001903'>anemia</z:hpo> in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>With the intention of improving survival and growth of early erythroid progenitors we investigated the effect of stem-cell factor (SCF) and interleukin-3 (IL-3) alone and in combination with erythropoietin, on the in vitro erythropoiesis of 13 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and of three <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="2" pm="."><plain>SCF and IL-3 alone did not promote erythroid colony growth in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, while 3 cases responded to erythropoietin alone </plain></SENT>
<SENT sid="3" pm="."><plain>In each of these, BFU-E colony growth could be increased by SCF, which was also found in <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrows </plain></SENT>
<SENT sid="4" pm="."><plain>Altogether 6 cases showed a significant enhancement of BFU-E colony numbers by the combination of SCF and erythropoietin as compared to erythropoietin alone (P = 0.036) </plain></SENT>
<SENT sid="5" pm="."><plain>Out of the 6 responding cases, 5 belonged to the FAB-classified subgroups <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (RA/RS) (5/5), while 1 patient was classified as having <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) (1/4) </plain></SENT>
<SENT sid="6" pm="."><plain>No patient with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) (0/4) responded </plain></SENT>
<SENT sid="7" pm="."><plain>In spite of these positive effects, the absolute number of BFU-E colonies remained reduced in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases when compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="8" pm="."><plain>IL-3 proved ineffective in increasing the response to erythropoietin in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> although it increased erythropoietin-induced BFU-E formation in <z:mpath ids='MPATH_458'>normal</z:mpath> controls significantly </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that the striking synergistic effect of SCF and erythropoietin on erythroid colony formation seen with <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow is conserved in most cases with RA and RA/RS </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> the intrinsic defect of the erythroid differentiation pathway cannot be overcome by SCF </plain></SENT>
</text></document>